Wuhan Demeikai Biotechnology Co., Ltd
返回首页 | 加入收藏 | 设为首页
Wuhan Demeikai Biotechnology Co., Ltd
whatsapp:+86 18942921723(Ms.Gao) 
+86 13260607296(Mr.Wang)
Buy DM 1 powder /Mertansine Home您现在的位置:HOME >> PRODUCTS >> Inhibitors

Buy DM 1 powder /Mertansine

所属类别:Inhibitors 点击次数:824次 发布时间:2017-04-13

DM 1 /Mertansine
 DM 1 /Mertansine Basic Info.
Product Name:DM 1; N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine
Appearance:White to light yellow solid
Assay:NLT 95.0%
Mertansine Application:
Mertansine is a tubulin inhibitor,inhibits the assemblyof microtubules by binding to tubulin,  with a linker structure can create an antibody-drug conjugate (ADC).
In vitro: Maytansine is a potent microtubule-targeted compound that induces mitotic arrest and kills tumor cells at sub-nanomolar concentrations. Maytansine at a concentration of 100 nmol/L suppressed the growth and shortening rates by 35%, quantitatively similarly to the same concentration of vinblastine.  maytansine inhibits the formation of a cross-link between Cys 12 and Cys 201
To determine the maximum tolerated dose and pharmacokinetics of cantuzumab mertansine, an immunoconjugate of the potent maytansine derivative (DM1) and the humanized monoclonal antibody (huC242) directed to CanAg, intravenously (i.v.) once every 3 weeks and to seek evidence of antitumor activity.
Patients with CanAg-expressing solid malignancies were treated with escalating doses of cantuzumab mertansine administered i.v. every 3 weeks. The pharmacokinetic parameters of cantuzumab mertansine, the presence of plasma-shed CanAg, and the development of both human antihuman and human anti-DM1 conjugate antibodies also were characterized.
Thirty-seven patients received 110 courses of cantuzumab mertansine at doses ranging from 22 to 295 mg/m2. Acute, transient, and reversible elevations of hepatic transaminases were the principal toxic effects. Nausea, vomiting, fatigue, and diarrhea were common but rarely severe at the highest dose levels. Dose, peak concentration, and area under the concentration-time curve correlated with the severity of transaminase elevation. The mean (+/- SD) clearance and terminal elimination half-life values for cantuzumab mertansine averaged 39.5 (+/-13.1) mL/h/m2 and 41.1 (+/-16.1) hours, respectively. Strong expression (3+) of CanAg was documented in 68% of patients. Two patients with chemotherapy-refractory colorectal carcinoma had minor regressions, and four patients had persistently stable disease for more than six courses.
The recommended dose for cantuzumab mertansine is 235 mg/m2 i.v. every 3 weeks. The absence of severe hematologic toxic effects, preliminary evidence of cantuzumab mertansine tumor localization, and encouraging biologic activity in chemotherapy-refractory patients warrant further broad clinical development of this immunoconjugate in CanAg-expressing tumors.

上一产品: AZD6244/Selumetinib
下一产品: Buy MMAD powder MonoMethyl Dolastatin 10
友情链接:made-in-china | 西地那非原料药 | 伐地那非原料药 | 他达那非原料药 | 
Copyright © 2004-2015 Wuhan Demechem Bio-tech Co., Ltd All Rights Release all
whatsapp:8618942921723 Company address: wuchang district in wuhan city, hubei province austral soho north 4 1 unit。
  • QQ咨询

  • 电话咨询

  • 13260607296